

**COMMONWEALTH OF MASSACHUSETTS
Board of Registration in Pharmacy**

**NOTICE OF THE REGULARLY SCHEDULED MEETING OF THE
BOARD OF REGISTRATION IN PHARMACY**

November 2, 2023

The regular session is open to the public by video or phone.

Join link

<https://eohhs.webex.com/eohhs/j.php?MTID=m1aee272d1136c95f9428d216b0164403>

Webinar number

2531 528 9272

Webinar password

J3pdNCKxu73 (53736259 from phones and video systems)

Join by phone

+1-617-315-0704 United States Toll (Boston)

+1-650-479-3208 United States Toll

Access code: 253 152 89272

*If you need reasonable accommodations in order to participate in the meeting, contact the DPH ADA Coordinator **Erin Bartlett**, erin.bartlett2@mass.gov or 857-262-7431 in advance of the meeting. While the Board will do its best to accommodate you, certain accommodations may require distinctive requests or the hiring of outside contractors and may not be available if requested immediately before the meeting.*

Agenda

Time	#	Item
8:00	I	CALL TO ORDER
8:02	II	APPROVAL OF AGENDA
8:05	III	APPROVAL OF BOARD MINUTES <ul style="list-style-type: none">Draft of October 5, 2023 Regular Session Minutes
8:10	IV	REPORTS <ul style="list-style-type: none">Applications approved pursuant to Licensure Policy 13-01Monthly report from ProbationBoard Delegated Review pursuant to Licensure Policy 14-02PSUD Report-Policy 17-03

8:15	V	FLEX <ul style="list-style-type: none">Nomination of Board OfficersProposed Board meetings for 2024Thank you to Jenny ChinELX Update																																																
9:00	VI	APPLICATIONS <ul style="list-style-type: none">Cornerstone Health Solutions - DS90083- Removal from Pilot Status RequestCVS/Specialty; DS3416 - Renovation																																																
9:20	VII	POLICIES <p>Policy 14-02: Board Delegated Review (BDR): The "unknown loss protocol" was removed from the policy since the Board voted for a new "controlled substance loss protocol" at the October meeting. Also added was the ability for BDR to issue a reprimand for the loss of less than #100 units of a Schedule II controlled substance.</p> <p>Policy 2021-04: Continuing Education (CE) Requirements for Pharmacists: Details for the required pain management training for CDTM pharmacists was added to the CE policy. With this addition, we request that the advisory titled "Pain Management Training for CDTM Pharmacists" be rescinded.</p> <p>Policy 2023-01: Compliance Packaging and Reusable Dose Planners Th change to this policy allows Schedule II and III maintenance medications to be placed in multi-drug-single-dose compliance packages.</p>																																																
9:30	VIII	RECONSIDERATION <ul style="list-style-type: none">Innocent Akani; PHA-2022-0119; PH25261																																																
9:45	IX	FILE REVIEW <table><tr><td>1</td><td>CAS-2023-0539</td><td>PHA-2023-0090</td><td>Springfield Pharmacy, DS90353</td></tr><tr><td>2</td><td>CAS-2023-0569</td><td>PHA-2023-0103</td><td>SaVcare Pharmacy, DS90261</td></tr><tr><td>3</td><td>CAS-2023-0559</td><td>PHA-2023-0101</td><td>Walgreens #10128, DS3472</td></tr><tr><td>4</td><td>CAS-2023-0012</td><td>PHA-2023-0142</td><td>Domenico Carbone, PH16514</td></tr><tr><td>5</td><td>CAS-2023-0899</td><td>PHA-2023-0157</td><td>Wal-Mart 10-2629, DS3508</td></tr><tr><td>6</td><td>CAS-2023-0864</td><td>PHA-2023-0140</td><td>Baystate Specialty Pharmacy, DS90099</td></tr><tr><td>7</td><td>CAS-2023-0815</td><td>PHA-2023-0148</td><td>Nicholas Gopal, PH239310</td></tr><tr><td>8</td><td>CAS-2023-0969</td><td>PHA-2023-0164</td><td>Rite Aid #10084, DS2780</td></tr><tr><td>9</td><td>CAS-2023-0655</td><td>PHA-2023-0116</td><td>CVS #209, DS89915</td></tr><tr><td>10</td><td>CAS-2023-0810</td><td>PHA-2023-0152</td><td>CVS #1893, DS2355</td></tr><tr><td>11</td><td>CAS-2023-0965</td><td>PHA-2023-0158</td><td>CVS #507, DS89841</td></tr><tr><td>12</td><td>CAS-2023-0802</td><td>PHA-2023-0150</td><td>CVS #117, DS3207</td></tr></table>	1	CAS-2023-0539	PHA-2023-0090	Springfield Pharmacy, DS90353	2	CAS-2023-0569	PHA-2023-0103	SaVcare Pharmacy, DS90261	3	CAS-2023-0559	PHA-2023-0101	Walgreens #10128, DS3472	4	CAS-2023-0012	PHA-2023-0142	Domenico Carbone, PH16514	5	CAS-2023-0899	PHA-2023-0157	Wal-Mart 10-2629, DS3508	6	CAS-2023-0864	PHA-2023-0140	Baystate Specialty Pharmacy, DS90099	7	CAS-2023-0815	PHA-2023-0148	Nicholas Gopal, PH239310	8	CAS-2023-0969	PHA-2023-0164	Rite Aid #10084, DS2780	9	CAS-2023-0655	PHA-2023-0116	CVS #209, DS89915	10	CAS-2023-0810	PHA-2023-0152	CVS #1893, DS2355	11	CAS-2023-0965	PHA-2023-0158	CVS #507, DS89841	12	CAS-2023-0802	PHA-2023-0150	CVS #117, DS3207
1	CAS-2023-0539	PHA-2023-0090	Springfield Pharmacy, DS90353																																															
2	CAS-2023-0569	PHA-2023-0103	SaVcare Pharmacy, DS90261																																															
3	CAS-2023-0559	PHA-2023-0101	Walgreens #10128, DS3472																																															
4	CAS-2023-0012	PHA-2023-0142	Domenico Carbone, PH16514																																															
5	CAS-2023-0899	PHA-2023-0157	Wal-Mart 10-2629, DS3508																																															
6	CAS-2023-0864	PHA-2023-0140	Baystate Specialty Pharmacy, DS90099																																															
7	CAS-2023-0815	PHA-2023-0148	Nicholas Gopal, PH239310																																															
8	CAS-2023-0969	PHA-2023-0164	Rite Aid #10084, DS2780																																															
9	CAS-2023-0655	PHA-2023-0116	CVS #209, DS89915																																															
10	CAS-2023-0810	PHA-2023-0152	CVS #1893, DS2355																																															
11	CAS-2023-0965	PHA-2023-0158	CVS #507, DS89841																																															
12	CAS-2023-0802	PHA-2023-0150	CVS #117, DS3207																																															

		FILE REVIEW			
		13	CAS-2023-0937	PHA-2023-0162	CVS #1204, DS2239
		14	CAS-2023-0339	PHA-2023-0075	CVS #730, DS1048
		15	CAS-2023-0532	PHA-2023-0092	CVS #1253, DS1961
		16	CAS-2023-0744	SA-INV-22287	Coram CVS/ Specialty Infusion Services, DS3601
		17	CAS-2023-0599	SA-INV-22167	CVS #38, DS3510
		18	CAS-2023-0663	PHA-2023-0117	CVS #4471, DS3552
		19	CAS-2023-0767	PHA-2023-0133	CVS #1576. DS3505
11:30	X	EXECUTIVE SESSION The Board will meet in Executive Session as authorized pursuant to M.G.L. c. 30A, § 21(a)(1) for the purpose of discussing the reputation, character, physical condition, or mental health, rather than professional competence, of an individual, or to discuss the discipline or dismissal of, or complaints or charges brought against, a public officer, employee, staff member or individual. Specifically, to evaluate the Good Moral Character as required for registration for a pending applicant.			
12:00		LUNCH BREAK			
2:00	XI	M.G.L. c. 112, § 65C SESSION			
4:00	XII	ADJOURNMENT			